In the high-stakes world of pharmaceutical development, the graveyard of "shelved" assets is vast. According to Annette Bakker, PhD, CEO of the Children’s Tumor Foundation (CTF), there are currently more than 5,000 potential drug candidates sitting idle on the shelves of major pharmaceutical companies. These are not necessarily failed drugs; many have undergone rigorous preclinical testing, toxicology studies, and even early-stage clinical trials, representing hundreds of millions of dollars in investment. Yet, for reasons often unrelated to their efficacy or safety, they are relegated to digital and physical archives, collecting dust as companies pivot their strategic focus or prioritize more lucrative blockbuster markets.
For the rare disease community, these shelved assets represent a profound missed opportunity. As the nonprofit sector increasingly pivots to act as a "drug discovery engine," organizations like the CTF are proving that they can bridge the "valley of death" between a shelved molecule and a life-changing therapy.
The Mechanics of Abandoned Innovation
The phenomenon of the "shelved asset" is a byproduct of the modern pharmaceutical business model. Large pharma companies frequently acquire smaller, innovative biotechs specifically to secure a single, high-potential candidate. Once the acquisition is complete, the parent company often undergoes a portfolio pruning process. Assets that do not fit the immediate commercial strategy—or those that represent a lower projected return on investment—are sidelined.
"Shelved assets are our focus because they have already undergone a massive amount of development," Bakker explains. "A company has often spent years and hundreds of millions of dollars on them, and they are eventually written off as a loss. What if we could take those and put them directly into clinical trials? We could effectively ‘win’ those lost years of preclinical and toxicology work and move into the clinical phase almost immediately."
The tragedy, however, is that when a biotech company fails or an asset is deprioritized, the vital data associated with those drugs often becomes inaccessible, trapped in the corporate silos of the original developer. This "data loss" complicates the efforts of patient advocacy groups and academic researchers to revive these promising programs.
Chronology of a Breakthrough: The SpringWorks Model
The potential of the nonprofit-driven rescue model is best illustrated by the success story of Gomekli (nirogacestat). The drug, which targets the genetic conditions associated with neurofibromatosis (NF)—a group of disorders causing tumors to grow on nerves—was once a neglected asset within the Pfizer pipeline.
The Timeline of Success:
- Early Research Phase: The Children’s Tumor Foundation began funding early-stage research into MEK inhibitors, establishing the scientific foundation for treating NF.
- The Partnership Bridge: Recognizing the potential of a shelved Pfizer asset, Annette Bakker engaged in high-level discussions with internal champions at Pfizer, including Louis Hall and Laura Sullivan.
- The Spin-off Strategy (2017): Through these negotiations, Pfizer agreed to license the shelved asset to a newly formed entity, SpringWorks Therapeutics. This move allowed the drug to be developed independently of the parent company’s shifting priorities.
- FDA Approval (2023): After years of dedicated development, Gomekli received FDA approval, marking a significant milestone for the NF community.
- Market Validation (2024): The success of the strategy was further validated when Merck KGaA acquired SpringWorks Therapeutics for $3.4 billion, demonstrating the high market value of these "rescued" assets.
Supporting Data: The Rare Disease Burden
The urgency of this work is underscored by the epidemiology of rare diseases. NF1, for example, affects roughly 1 in 3,000 people. While this sounds significant, the patient population is highly dispersed across the globe, and the subset of patients with inoperable plexiform tumors—the specific demographic targeted by Gomekli—is even smaller.
This scarcity creates a unique set of obstacles:
- Clinical Trial Recruitment: With so few patients, filling a clinical trial is a slow, costly, and logistically complex endeavor.
- Resource Allocation: Traditional drug developers often view these small populations as insufficient to recoup development costs, leading to the "shelving" that Bakker describes.
- The Nonprofit Advantage: Nonprofits are uniquely positioned to solve these problems. Unlike a public company, which must answer to shareholders, organizations like the CTF possess direct access to patient registries and global networks. This allows for faster recruitment and a deeper understanding of the patient experience, which is invaluable for trial design.
The Human Factor: Building an Ecosystem
The success of the SpringWorks model is the exception, not the rule. Scaling this approach remains a formidable challenge. Bakker admits that while she is actively seeking "champions" within other pharmaceutical companies—individuals with the influence and the mandate to help unlock these assets—the process is often met with closed doors.
"Everything you do in drug discovery is ten times harder in rare disease," Bakker notes. To overcome this, the CTF has moved beyond simple funding to create a full-scale preclinical hub. This hub serves as a centralized network of preclinical models, providing a ready-made environment to stress-test assets the moment they are handed over by a corporate partner.
"The idea is to create an ecosystem that ensures that once we have the drug, we can be extremely efficient," she says. By standardizing the preclinical validation process, the foundation reduces the risk for potential partners and accelerates the timeline to human trials.
Implications for the Future of Drug Discovery
The model pioneered by the Children’s Tumor Foundation has broad implications for the pharmaceutical industry. It suggests that the future of rare disease drug development may not lie solely within the walls of Big Pharma, but in a collaborative "triad" structure:
- The Pharma Giant: Acts as the source of the initial, high-cost investment that would otherwise go to waste.
- The Nonprofit Engine: Acts as the curator, aggregator, and patient advocate that understands the specific biology and the clinical need.
- The Specialized Biotech: Acts as the agile vehicle that brings the drug through the final stages of regulatory approval.
If this model can be replicated across other rare disease areas—from rare cancers to orphan metabolic disorders—it could unlock thousands of therapies currently trapped in corporate "cold storage."
However, the industry faces a structural hurdle. To unlock these 5,000 assets, there must be a cultural shift within pharmaceutical boardrooms. Companies must move away from the "all or nothing" approach to asset management and toward a more fluid system where non-core assets are systematically "spun out" to nonprofits or specialized startups rather than simply left to wither.
Conclusion
The work being done by the Children’s Tumor Foundation serves as a blueprint for a new era of medical philanthropy. By treating shelved assets not as discarded waste, but as "pre-paid" scientific opportunities, organizations like the CTF are changing the economics of rare disease research.
As the industry faces increasing pressure to demonstrate value and improve patient outcomes, the "rescue" model offers a compelling path forward. The challenge, as Bakker rightly points out, is not in the science, but in the diplomacy. Finding the internal champions at the world’s largest pharmaceutical companies who are willing to "open the door" will be the deciding factor in whether these thousands of shelved drugs finally reach the patients who need them most.
For the millions of patients living with rare conditions, the race to rescue these assets is not just an exercise in data management—it is a race against time.
About the Author
